Incannex Q3 FY2025 net loss $3.97M, cash $6.71M, IHL-42X Phase 2 dosing done

Incannex Healthcare Inc.

2025-Q3 EPS reported -$0.84 vs consensus -$0.94 ▲ beat (+11.1%)

Net loss of $3.97M for quarter ended March 31, 2025, vs $6.03M same quarter last year.
Cash and equivalents $6.71M as of March 31, up from $2.09M at Dec 31, 2024, after $12.5M private placement.
Completed dosing of >120 patients in Phase 2 portion of RePOSA study for IHL-42X (OSA); topline data expected July 2025.
Reported positive PK/safety study results for IHL-42X; both active components bioavailable, comparable to reference drugs.
Formed OSA Clinical Advisory Board; appointed Alison Wimms (ResMed) as member.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.